Wedbush已将Replimune Group Inc.的股票评级从中性上调至“跑赢大盘”。与此同时,该机构将目标价从12美元大幅提升至19美元。这一调整反映了对Replimune未来前景的更为乐观的预期。
Wedbush已将Replimune Group Inc.的股票评级从中性上调至“跑赢大盘”。与此同时,该机构将目标价从12美元大幅提升至19美元。这一调整反映了对Replimune未来前景的更为乐观的预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.